CMS · 25MG

CMS-121 is a small-molecule fisetin derivative studied for its activity as a fatty acid synthase (FASN) and acetyl-CoA carboxylase 1 (ACC1) inhibitor. In research models, it is investigated for reducing lipid peroxidation, modulating brain lipid metabolism, and protecting against oxytotic/ferroptotic cell death. Originally developed at the Salk Institute as a candidate for Alzheimer's disease and age-related cognitive decline, CMS-121 has also been examined in the literature for its effects on diet-induced obesity, type 2 diabetes models, kidney function, and overall geroprotection.

Benefits (Research Focus)

• Studied as a fatty acid synthase (FASN) and ACC1 inhibitor
• Explored for neuroprotective effects in transgenic Alzheimer's models
• Investigated for reducing lipid peroxidation and ferroptotic cell death
• Examined for cognitive function and memory in aged animal models
• Researched for metabolic effects in obesity and type 2 diabetes models

What Researchers Look At

• Lipid peroxidation and oxytosis/ferroptosis pathways
• Brain acetyl-CoA metabolism and histone acetylation
• Cognitive performance and memory in aged or transgenic AD models
• Hepatic and renal markers of inflammation and aging
• Glucose, insulin, and lipid markers in diabetic models

Quick Specs

• Form: Gelatin Capsule
• Strength: 25 mg/capsule
• Quantity: 30 capsules per bottle
• Excipient: Microcrystalline cellulose (MCC) — pharmaceutical-grade filler
• Storage: Store in a cool, dry, dark place

Identity Basics

• Compound: CMS-121
• Chemical Name: 4-[4-(Cyclopentyloxy)quinolin-2-yl]benzene-1,2-diol
• Chemical Formula: C₂₀H₁₉NO₃
• Molecular Weight: 321.38 g/mol
• CAS: 1353224-53-9

Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.